Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Tuesday, Benzinga reports. The firm currently has a $1,189.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a neutral rating in a research report on Tuesday, February 6th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an outperform rating and a $1,125.00 price objective for the company. Truist Financial restated a buy rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a research note on Monday, February 5th. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, January 5th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $968.67.

Regeneron Pharmaceuticals Stock Up 0.6 %

REGN stock opened at $943.89 on Tuesday. The company has a fifty day moving average price of $959.25 and a 200 day moving average price of $887.65. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a market cap of $103.60 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.75 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the firm earned $10.96 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 38.18 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares of the company’s stock, valued at $6,062,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Sunbelt Securities Inc. bought a new position in Regeneron Pharmaceuticals in the first quarter worth $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. O Dell Group LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $27,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Finally, MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.